
Sign up to save your podcasts
Or


How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
By Medscape4.3
2525 ratings
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu

135 Listeners

708 Listeners

504 Listeners

167 Listeners

103 Listeners

906 Listeners

14 Listeners

16 Listeners

297 Listeners

268 Listeners

3,383 Listeners

1,143 Listeners

196 Listeners

90 Listeners

520 Listeners

365 Listeners

173 Listeners

60 Listeners

8 Listeners

436 Listeners